 |
||||
| 2007 JASN IMPACT FACTOR 7.111 | HOME AUTHOR INFO EDITORIAL BOARD SUBSCRIBE FEEDBACK ALERTS HELP | |||
| CURRENT ISSUE | ARCHIVES | JASN Express | ONLINE SUBMISSION | |
|
||||
| 2007 JASN IMPACT FACTOR 7.111 | HOME AUTHOR INFO EDITORIAL BOARD SUBSCRIBE FEEDBACK ALERTS HELP | |||
| CURRENT ISSUE | ARCHIVES | JASN Express | ONLINE SUBMISSION | |
BASIC SCIENCE |
*Nephrological Center, Medical Policlinic, Ludwig-Maximilians-University Munich, Germany; Department of Immunology, Berlex Biosciences, Richmond, California; Department of Pathology, University of Washington, Seattle, Washington; and Department of Pathology, Hospital Ramon y Cajal, Universidad de Alcala, Madrid, Spain
Correspondence to Dr. H.-J. Anders, Medizinische Poliklinik der LMU, Pettenkoferstrasse 8a, 80336 Munich, Germany. Phone: ++49-89-5996846; Fax: ++49-89-5996860; E-mail: hjanders{at}med.uni-muenchen.de
ABSTRACT. Slowly progressive renal injury is the major cause for ESRD. The model of progressive immune complex glomerulonephritis in autoimmune MRLlpr/lpr mice was used to evaluate whether chemokine receptor CCR1 blockade late in the disease course can affect progression to renal failure. Mice were treated with subcutaneous injections of either vehicle or BX471, a nonpeptide CCR1 antagonist, three times a week from week 20 to 24 of age. BX471 improved blood urea nitrogen levels (BX471, 35.1 ± 5.3; vehicle, 73.1 ± 39.6 mg/dl; P < 0.05) and reduced the amount of ERHR-3 macrophages, CD3 lymphocytes, Ki-67 positive proliferating cells, and ssDNA positive apoptotic cells in the interstitium but not in glomeruli. Cell transfer studies with fluorescence-labeled T cells that were pretreated with either vehicle or BX471 showed that BX471 blocks macrophage and T cell recruitment to the renal interstitium of MRLlpr/lpr mice. This was associated with reduced renal expression of CC chemokines CCL2, CCL3, CCL4, and CCL5 and the chemokine receptors CCR1, CCR2, and CCR5. Furthermore, BX471 reduced the extent of interstitial fibrosis as evaluated by interstitial smooth muscle actin expression and collagen I deposits, as well as mRNA expression for collagen I and TGF-
. BX471 did not affect serum DNA autoantibodies, proteinuria, or markers of glomerular injury in MRLlpr/lpr mice. This is the first evidence that, in advanced chronic renal injury, blockade of CCR1 can halt disease progression and improve renal function by selective inhibition of interstitial leukocyte recruitment and fibrosis.
This article has been cited by other articles:
 |
|
 |
|
  K. Furuichi, J.-L. Gao, R. Horuk, T. Wada, S. Kaneko, and P. M. Murphy Chemokine Receptor CCR1 Regulates Inflammatory Cell Infiltration after Renal Ischemia-Reperfusion Injury J. Immunol., December 15, 2008; 181(12): 8670 - 8676. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J.-E. Turner, H.-J. Paust, O. M. Steinmetz, A. Peters, C. Meyer-Schwesinger, F. Heymann, U. Helmchen, S. Fehr, R. Horuk, U. Wenzel, et al. CCR5 Deficiency Aggravates Crescentic Glomerulonephritis in Mice J. Immunol., November 1, 2008; 181(9): 6546 - 6556. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M Mamtani, B Rovin, R Brey, J F Camargo, H Kulkarni, M Herrera, P Correa, S Holliday, J-M Anaya, and S K Ahuja CCL3L1 gene-containing segmental duplications and polymorphisms in CCR5 affect risk of systemic lupus erythaematosus Ann Rheum Dis, August 1, 2008; 67(8): 1076 - 1083. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Giannopoulou, C. Dai, X. Tan, X. Wen, G. K. Michalopoulos, and Y. Liu Hepatocyte Growth Factor Exerts Its Anti-Inflammatory Action by Disrupting Nuclear Factor-{kappa}B Signaling Am. J. Pathol., July 1, 2008; 173(1): 30 - 41. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Schiffer, R. Bethunaickan, M. Ramanujam, W. Huang, M. Schiffer, H. Tao, M. M. Madaio, E. P. Bottinger, and A. Davidson Activated Renal Macrophages Are Markers of Disease Onset and Disease Remission in Lupus Nephritis J. Immunol., February 1, 2008; 180(3): 1938 - 1947. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V. Mayer, K. L. Hudkins, F. Heller, H. Schmid, M. Kretzler, U. Brandt, H.-J. Anders, H. Regele, P. J. Nelson, C. E. Alpers, et al. Expression of the chemokine receptor CCR1 in human renal allografts Nephrol. Dial. Transplant., June 1, 2007; 22(6): 1720 - 1729. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. Ninichuk, A. G. Khandoga, S. Segerer, P. Loetscher, A. Schlapbach, L. Revesz, R. Feifel, A. Khandoga, F. Krombach, P. J. Nelson, et al. The Role of Interstitial Macrophages in Nephropathy of Type 2 Diabetic db/db Mice Am. J. Pathol., April 1, 2007; 170(4): 1267 - 1276. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 U. Panzer, O. M. Steinmetz, R. R. Reinking, T. N. Meyer, S. Fehr, A. Schneider, G. Zahner, G. Wolf, U. Helmchen, P. Schaerli, et al. Compartment-Specific Expression and Function of the Chemokine IP-10/CXCL10 in a Model of Renal Endothelial Microvascular Injury J. Am. Soc. Nephrol., February 1, 2006; 17(2): 454 - 464. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. S. Duffield, P. G. Tipping, T. Kipari, J.-F. Cailhier, S. Clay, R. Lang, J. V. Bonventre, and J. Hughes Conditional Ablation of Macrophages Halts Progression of Crescentic Glomerulonephritis Am. J. Pathol., November 1, 2005; 167(5): 1207 - 1219. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. Ninichuk, O. Gross, C. Reichel, A. Khandoga, R. D. Pawar, R. Ciubar, S. Segerer, E. Belemezova, E. Radomska, B. Luckow, et al. Delayed Chemokine Receptor 1 Blockade Prolongs Survival in Collagen 4A3-Deficient Mice with Alport Disease J. Am. Soc. Nephrol., April 1, 2005; 16(4): 977 - 985. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H.-J. Anders, V. Vielhauer, and D. Schlondorff Current paradigms about chemokines as therapeutic targets Nephrol. Dial. Transplant., December 1, 2004; 19(12): 2948 - 2951. [Full Text] [PDF]
|
|
|
HOME
CURRENT ISSUE
ARCHIVES
JASN Express
ONLINE SUBMISSION
AUTHOR INFO
EDITORIAL BOARD SUBSCRIBE FEEDBACK ALERTS HELP |
Copyright © 2008 by the American Society of Nephrology. Online ISSN: 1533-3450 Print ISSN: 1046-6673
